Inhibition of B16 melanoma metastasis by the immunomodulator AS101

International Journal of Oncology

Volumn 9, Issue 2, 1996, Pages 319-325

  Xu, Ren He ^a   Kalechman, Yona ^b   Albeck, Michael ^b   Kung, Hsiang Fu ^a   Sredni, Benjamin ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

AS101; Immunomodulator; Melanoma; Metastasis; Mouse; Natural killer cell; Retinoblastoma

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; COLONY STIMULATING FACTOR; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG METASTASIS; MELANOMA; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

EID: 0030018206     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.9.2.319     Document Type: Article

References (40)

1. Grimm EA, Mazumder A, Zhang HZ and Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autonomous human peripheral blood lymphocytes. J Exp Med 155: 1823-1841, 1982.
2. Rosenberg S, Lotze M, Muul L, Chang A, Avis F, Leitman S, Robertson C, Lee R, Ribin J, Seipp C, Simpson C and White D: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889-897, 1987.
3. Rosenberg S, Spiess P and Lafraniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 223: 1218-1221, 1986.
4. Rosenberg S, Aebersold P, Cornetta K, Kasid A, Morgan R, Moen R, Karson E, Lotze M, Yang J, Topalian SL, Merino MJ, Culver K, Miller AD, Blaese RM and Anderson WF: Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323: 570-578, 1990.
5. Tepper R, Pattengale P and Leder P: Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503-512, 1989.
6. Barth A, Hoon D, Foshag L, Nizze J, Famatiga E, Okun E and Morton D: Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 54: 3342-3345, 1994.
7. Chapman P, Livingston P, Morrison M, Williams L and Houghton A: Immunization of melanoma patients with antiidiotypic monoclonal antibody BECII (which mimics GD3 ganglioside): pilot trial using no immunological adjuvant. Vaccine Res 3: 59-69, 1994.
8. Rosenberg S, Lotze M, Yang J, Linehan W, Seipp C, Calabro S, Karp S, Sherry R, Steinberg S and White D: Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7: 1863-1874, 1989.
9. Rosenberg S, Lotze M, Yang J, Aebersold P, Linehan W, Seipp C and White D: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474-484, 1989.
10. Cascinelli N, Bufalino R, Morabito A and Mackie R: Results of adjuvant interferon study in WHO melanoma programme. Lancet 343: 913-914, 1994.
11. Mukherji B and Chakraborty NG: Immunobiology and immunotherapy of melanoma. Curr Opin Oncol 7: 175-184, 1995.
12. Sredni B, Caspi RR, Klein A, Kalechman Y, Danziger Y, Ben Ya'akov M, Tamari T, Shalit F and Albeck M: A new immunomodulating compound (AS101) with potential therapeutic application. Nature 330: 173-176, 1987.
13. Sredni B, Kalechman Y, Albeck M, Gross O, Aurbach D, Sharon P, Sehgal SN, Gurwith M and Michlin H: Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase-C inducer bryostatin. Immunology 70: 473-477, 1990.
14. Sredni B, Kalechman Y, Shalit F and Albeck M: Synergism between AS101 and PMA in lymphokine production. Immunology 69: 110-116, 1990.
15. Kalechman Y, Zuloff A, Albeck M, Strassmann G and Sredni B: Role of endogenous cytokines secretion in radioprotection conferred by the immunomodulator ammonium trichloro (dioxyethylene-0-0′)tellurate. Blood 85: 1555-1561, 1995.
16. Sredni B, Albeck M, Tichler T, Shani A, Shapira J, Bruderman I, Catane R, Kaufman B and Kalechman Y: Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. J Clin Oncol 13: 2342-2353, 1995.
17. Kalechman Y, Albeck M, Oron M, Sobelman D, Gurwith M, Sehgal SN and Sredni B: The radioprotecitve effects of the immunomodulator AS101. J Immunol 145: 1512-1517, 1990.
18. Kalechman Y, Albeck M, Oron M, Sobelman D, Gurwith M, Horwith G, Kirsch T, Maida B, Sehgal SN and Sredni B: Protective and restorative role of AS101 in combination with chemotherapy. Cancer Res 51: 1499-1503, 1991.
19. Kalechman Y, Rushkin G, Nerubay J, Albeck M and Sredni B: Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, arid anemia in mice. Exp Hematol 23: 1358-1366, 1995.
20. Sredni B, Xu RH, Albeck M, Gafter U, Gal R, Shani A, Tichler T, Shapira J, Bruderman I, Catane R, Kaufman B, Whisnanty JK, Mettinger KL and Kalechman Y: The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia. Studies on human and animal models. Int J Cancer 65: 97-103, 1996.
21. Hanna N and Burton RC: Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastasis in vivo. J Immunol 127: 1754-1758, 1981.
22. Barlozzari T, Leonhardt J, Wiltrout RH, Herberman RB and Reynolds CW: Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol 134: 2783-2789, 1985.
23. Luster MI, Munson AE, Thomas PT, Holsapple MP, Fenters JD, White KL, Lauer LD, Germolec DR, Rosenthal GJ and Dean JH: Development of a testing battery to assess chemical-induced immunotoxicity: National program's guidelines for immunotoxicity evaluation in mice. Fund Appl Toxicol 10: 2-19, 1988.
24. Pope BL, Chourmouzis E, Sigindere J, Maclntyre PJ, Capetola R and Lau CY: In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine). Cell Immunol 147: 302-312, 1993.
25. Fidler IJ, Gersten DM and Riggs CW: Relationship of host immune status to tumor cell arrest, distribution and survival in experimental animals. Cancer 40: 46-55, 1977.
26. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC and White RL: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305: 779-784, 1983.
27. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
28. Prica JE, Aukerman SL and Fidler I: Evidence that the process of murine pulmonary melanoma metastasis is sequential and selective and contains stochastic elements. Cancer Res 46: 5172-5178, 1986.
29. Fidler IJ and Talmadge JE: Evidence that intravenously derived murine pulmonary melanoma metastases can originate from the expansion of a single tumor cell. Cancer Res 46: 5167-5171, 1986.
30. Post G, Doll J, Brown AE, Tzeng J and Zeidmen I: Comparison of the metastatic properties of B16 melanoma clones isolated from cultured cell lines, subcutaneous tumors and individual lung metastases. Cancer Res 42: 2770-2778, 1982.
31. Hill RP, Chambers AF, Ling V and Harris JF: Dynamic heterogeneity: Rapid generation of metastatic variants in mouse B16 melanoma cells. Science 224: 998-1001, 1984.
32. Yogeeswaran G and Salk PL: Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science 212: 1514-1516, 1981.
33. Cohen SA, Tzung SP, Doerr RJ and Goldrosen MH: Role of asialo-GM1 positive liver cells from athymic nude or polyinosinic-polycytidilic acid-treated mice in suppressing colon-derived experimental hepatic metastasis. Cancer Res 50: 1834-1840, 1990.
34. Seaman WE, Sleisenger M, Eriksson E and Koo GC: Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1 Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol 138: 4539-4544, 1987.
35. Sharma BS, Balazs L, Jin A, Jolley WB and Robins RK: Successful immunothcrapy of murine melanoma metastases with 7-thia-8-oxoguanosine. Clin Exp Metastasis 9: 429-439, 1991.
36. Herberman R and Ortaldo J: Natural killer cells: their role in defences against disease. Science 214: 24-29, 1981.
37. Hill L, Perussia B, McCue P and Korngold R: Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. Cancer Res 54: 763-770, 1994.
38. Bookstein R, Shew JY, Chen PL, Scully P and Lee WH: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247: 712-715, 1990.
39. Lee EYHP, To H, Shew JY, Bookstein R, Scully P and Lee WH: Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241: 218-221, 1988.
40. Xu RH, Kalechman Y, Albeck M and Sredni B: The cytoprotective effect of the immunomodulator AS101 against hydrochloride induced gastric lesions. Res Commun Mol Pathol Pharmacol 87: 4-20, 1995.